Combination therapy for chronic active Epstein-Barr virus disease
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests two drugs, golidocitinib and selinexor, given together to treat chronic active Epstein-Barr virus disease (CAEBVD). The goal is to see if this combination can help control the disease better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been diagnosed with chronic active Epstein-Barr virus disease based on current guidelines.
- You must be well enough to perform daily activities without help (ECOG score 0 or 1).
- Your liver and kidney function must be within certain limits (blood tests will confirm).
- Your blood counts must meet minimum levels (neutrophils, platelets, and hemoglobin).
- You cannot have other cancers, active infections, or have had certain prior treatments like a JAK inhibitor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a type of immune cell called iNK can help treat chronic active EBV or EBV-related high inflammation that remains after a stem cell transplant. It may be an option for people who still have signs of EBV in their blood, spinal fluid, bone marrow, or scans after transplant.
This trial studies whether a specific treatment (a chemotherapy-based induction plan plus a PD-1 antibody) can improve outcomes in adults with lymphoma-associated HLH caused by Epstein-Barr virus (EBV). It aims to better control the overactive immune disease driving HLH and lymphoma.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests a new immune therapy for people with Epstein-Barr virus (EBV)-related lymphoproliferative diseases, including chronic active EBV and conditions that can occur after an organ or stem cell transplant. It aims to see if the therapy can safely control the disease.
Hear when a new EBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.